To anti-abortion activists who worked diligently to help President Trump win in 2024 and deliver a Republican trifecta, the Food and Drug Administration’s (FDA) decision last week to approve a generic version of mifepristone — a pill used in medication abortions — was a slap in the face.
The “pro-life” community is well aware that in the aftermath of the Dobbs decision, it’s not prudent politics to take a purist stance on issues like a natio...